Company profile
Pleco Therapeutics company profile
Pleco Therapeutics' aim is to establish the market value and therapeutic potential of our patented PlecoidTM medications by focusing first on orphan cancer treatments. Current pre-clinical development activities at the firm are focused on the development of medicines for Acute Myeloid Leukaemia (AML), a relatively rare blood cancer, and Small-Cell Lung Cancer (SCLC), an aggressive subtype of lung cancer. Both diseases carry a poor prognosis.
Business identity
- Contact email
- [email protected]
- Phone number
- +31-61-132-5510
- Operating status
- Active
- Company type
- For Profit
- Employee range
- 11-50 employees
- Revenue range
- $0-$1M
- Founded
- 2018-01-01, Year
Headquarters
- Headquarters
- Nijmegen, Gelderland, The Netherlands
- Postal code
- 6534 AB
- Country code
- NL
- Continent
- Europe